Clinical trials: aldesleukin
Recurrent Melanoma, Stage IV Melanoma
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
This phase I/II trial is studying the side effects of giving laboratory-treated T cells and ipilimumab together to see how well they work in treating patients with metastatic melanoma.
- Trial name
- NCT00871481
- Testing
- ipilimumab, cyclophosphamide, biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fred Hutchinson Cancer Center
Transplantation, Liver Diseases
Low-dose IL-2 for Treg Expansion and Tolerance (LITE)
Regulatory T cells (Tregs) suppress cytopathic immune responses and inhibit transplant rejection. Our goal is to exploit the Treg suppressive properties to induce transplantation tolerance.
- Trial name
- LITE (NCT02949492)
- Testing
- IL-2 (interleukin 2)
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- King's College London
Kidney Cancer, Melanoma (Skin)
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00276835
- Testing
- High-dose interleukin-2, genistein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma and Plasma Cell Neoplasm
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Biological therapies, such as interferon-gamma and aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00616720
- Testing
- aldesleukin, idiotype-pulsed autologous dendritic cell vaccine APC8020, recombinant interferon gamma
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Uveal Neoplasms, Melanoma, Uveal
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
This is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with metastatic uveal melanoma will be…
- Trial name
- NCT03467516
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Udai Kammula
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with…
- Trial name
- NCT07011004
- Testing
- Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
Objectives: The primary objective will be to determine whether patients receiving the combination of dendritic cells and high dose IL-2 (Cohort A) have sustained persistence of infused T cells compared to patients treated with T…
- Trial name
- NCT00338377
- Testing
- Dendritic Cell Immunization, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1,230 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers may become resistant to chemotherapy drugs.
- Trial name
- NCT00002925
- Testing
- ara-C, Daunorubicin, Etoposide
- Where
- 33 sites in United States
- Volunteers
- 410 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00871689
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Cancer, Colorectal Cancer
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT03935893
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Fludarabine + Cyclophosphamide combination
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Udai Kammula
HIV Infections
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
Effective, suppressive treatment for HIV infected patients can be a major challenge because HIV progressively destroys their immune systems.
- Trial name
- NCT00110578
- Testing
- Adoptive transfer of HIV-specific CD8+ T cells, Aldesleukin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)